Reslizumab
drugOn this page
Also known as CEP-38072CinqaeroCinqairCinquilDCP 835DCP-835SCH 55700SCH-55700SCH55700
Summary
Reslizumab (CHEMBL2107884) is an approved antibody (ATC R03DX08); indicated across 8 conditions including obstructive lung disease and asthma.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Antibody
- ATC class: R03DX08
- Indications: 8 conditions
- Clinical trials: 22
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2107884 |
| Name | Reslizumab |
| Type | Antibody |
| Max phase | 4 |
| ATC | R03DX08 |
Also known as: CEP-38072, Cinqaero, Cinqair, Cinquil, DCP 835, DCP-835, Reslizumab, SCH 55700, SCH-55700, SCH55700, RESLIZUMAB
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
8 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| obstructive lung disease | 4 | MONDO:0002267 | HP:0006536 |
| asthma | 4 | MONDO:0004979 | MONDO:0004979 |
| eosinophilic esophagitis | 3 | MONDO:0005361 | EFO:0004232 |
| sinusitis | 3 | MONDO:0005961 | EFO:0007486 |
| substance-related disorder | 3 | MONDO:0002494 | MONDO:0004938 |
| loiasis | 2 | MONDO:0016566 | EFO:1000729 |
| bronchitis | 2 | MONDO:0003781 | EFO:0009661 |
| hypereosinophilic syndrome | 2 | MONDO:0015691 | EFO:1001467 |
Clinical trials
Total trials: 22.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 10 |
| PHASE2 | 5 |
| PHASE4 | 2 |
| PHASE2/PHASE3 | 2 |
| Not specified | 2 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT02937168 | PHASE4 | TERMINATED | An Imaging Study Using PET/CT to Characterize the Effect of Intravenous Reslizumab on Airway Inflammation |
| NCT04710134 | PHASE4 | COMPLETED | Efficacy of Reslizumab Dose Escalation in Patients With Severe Asthma |
| NCT00538434 | PHASE2/PHASE3 | COMPLETED | Efficacy and Safety Study of Reslizumab to Treat Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years |
| NCT00635089 | PHASE3 | COMPLETED | Open-Label Extension Study of Reslizumab in Pediatric Subjects With Eosinophilic Esophagitis |
| NCT01270464 | PHASE3 | COMPLETED | A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma |
| NCT01285323 | PHASE3 | COMPLETED | A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma |
| NCT01287039 | PHASE3 | COMPLETED | A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma |
| NCT01290887 | PHASE3 | TERMINATED | Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma |
| NCT01508936 | PHASE3 | COMPLETED | Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma |
| NCT02452190 | PHASE3 | COMPLETED | Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils |
| NCT02501629 | PHASE3 | COMPLETED | An Efficacy and Safety Study of Reslizumab Subcutaneous in Patients With Oral Corticosteroid Dependent Asthma and Elevated Blood Eosinophils |
| NCT02559791 | PHASE2/PHASE3 | COMPLETED | Anti-Interleukin-5 (IL5) Monoclonal Antibody (MAb) in Prednisone-dependent Eosinophilic Asthma |
| NCT02799446 | PHASE3 | UNKNOWN | Effect of Reslizumab in Chronic Rhinosinusitis |
| NCT03052725 | PHASE3 | TERMINATED | A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma |
| NCT02947945 | PHASE2 | RECRUITING | Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study |
| NCT00017862 | PHASE2 | COMPLETED | Anti-Interleukin-5 Antibody to Treat Hypereosinophilic Syndrome |
| NCT00587288 | PHASE2 | COMPLETED | Efficacy and Safety Study of Reslizumab to Treat Poorly Controlled Asthma |
| NCT01111305 | PHASE2 | COMPLETED | Reslizumab to Prevent Post-treatment Eosinophilia in Loiasis |
| NCT03074942 | PHASE2 | COMPLETED | Reslizumab in Patients With Severe Asthma Who Failed to Respond to Omalizumab |
| NCT04183192 | PHASE1 | COMPLETED | Pharmacodynamic Biomarkers to Support Biosimilar Development: Interleukin-5 Antagonists |
| NCT03369574 | Not specified | WITHDRAWN | Study of Chronic Rhinosinusitis Symptoms in Asthma Patients Undergoing Treatment With Reslizumab |
| NCT04665141 | Not specified | UNKNOWN | Similarities and Differences of Biological Therapies for Severe Asthma. |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).